NEW YORK (GenomeWeb News) — MDS today yesterday reported that third-quarter revenue for the segment comprising its MDS Sciex and Molecular Devices units increased 92 percent as organic receipts rose 11 percent and R&D spending doubled.
 
Total revenue for the three months ended July 31 increased to $127 million from $66 million for its MDS Analytical Technologies segment, which includes Sciex and Molecular Devices.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.